FDA Clears Magstim Horizon INSPIRE Transcranial Magnetic Stimulation System to treat Depression, OCD, Anxious Depression

Next Generation Compact TMS System Offers Physicians, Nurse Practitioners, New Easy to Use, Affordable Effective Treatment MINNEAPOLIS and CARMARTHENSHIRE, United Kingdom, Nov. 12, 2024 — Magstim, the global leader in neuroscience research and treatment for mental health, has been awarded FDA clearance for the Horizon Inspire System, continuing

Enlivex Announces the Enrollment and Dosing of the First 10 Patient in the Randomized Phase II Stage of its Allocetra Trial in Patients with Moderate to Severe Knee Osteoarthritis

Nes-Ziona, Israel, Nov. 12, 2024 — Enlivex Therapeutics Ltd. , a clinical-stage macrophage reprogramming immunotherapy company, today announced the enrollment and dosing of the first 10 patients in the randomized Phase II stage of the Company’s multi-country Phase I/II Allocetra™ trial in patients with moderate